

11/564,694

=> file caplus  
FILE 'CAPLUS' ENTERED AT 12:59:15 ON 05 SEP 2007  
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)


Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 5 Sep 2007 VOL 147 ISS 11  
FILE LAST UPDATED: 4 Sep 2007 (20070904/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

<http://www.cas.org/infopolicy.html>

=> d que  
L1 STR



Structure attributes must be viewed using STN Express query preparation.

L3 53 SEA FILE=REGISTRY SSS FUL L1  
L4 2 SEA FILE=CAPLUS L3

=> d 14 1-2 ibib abs hitstr

L4 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2007 ACS on STN  
ACCESSION NUMBER: 2006:733197 CAPLUS  
DOCUMENT NUMBER: 145:167098  
TITLE: Preparation of polymorphic crystalline forms of  
cis-5-fluoro-N-[4-(2-hydroxy-4-  
methylbenzamido)cyclohexyl]-2-(tetrahydrothiopyran-4-  
yloxy)nicotinamide  
INVENTOR(S): Murtagh, Lorraine Michelle; Taylor, Stefan Colin John;  
Willis, Niamh Josephine  
PATENT ASSIGNEE(S): Pfizer Limited, UK  
SOURCE: PCT Int. Appl., 33 pp.  
CODEN: PIXXD2  
DOCUMENT TYPE: Patent

LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006077497	A1	20060727	WO 2006-IB132	20060111
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
EP 1683795	A1	20060726	EP 2005-100400	20050121
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, BA, HR, IS, YU				
JP 2006199700	A	20060803	JP 2006-11909	20060120

PRIORITY APPLN. INFO.: EP 2005-100400 A 20050121  
GB 2005-1567 A 20050125  
US 2005-674986P P 20050425

AB Cis-5-fluoro-N-(4-(2-hydroxy-4-methylbenzoylamino)cyclohexyl)-2-(tetrahydrothiopyran-4-yloxy)nicotinamide is synthesized, its polymorphic crystalline forms prepared, and pharmaceutical formulations containing them are claimed.


IT 834868-88-1P 834869-01-1P  
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(in the preparation of polymorphic crystalline forms of  
 cis-5-fluoro-N-[4-(2-hydroxy-4-methylbenzamido)cyclohexyl]-2-(tetrahydrothiopyran-4-yloxy)nicotinamide)

RN 834868-88-1 CAPLUS

CN 3-Pyridinecarboxamide, N-(cis-4-aminocyclohexyl)-2-[(tetrahydro-2H-thiopyran-4-yl)oxy]-, monohydrochloride (9CI) (CA INDEX NAME)

Relative stereochemistry.



● HCl


RN 834869-01-1 CAPLUS

CN Carbamic acid, [cis-4-[[2-[(tetrahydro-2H-thiopyran-4-yl)oxy]-3-

11/564,694

pyridinyl]carbonyl]amino]cyclohexyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Relative stereochemistry.



IT 901768-34-1P

RL: CPS (Chemical process); PEP (Physical, engineering or chemical process); PRP (Properties); PYP (Physical process); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); PROC (Process); USES (Uses)


(preparation of polymorphic crystalline forms of

cis-5-fluoro-N-[4-(2-hydroxy-4-methylbenzamido)cyclohexyl]-2-(tetrahydrothiopyran-4-yloxy)nicotinamide)

RN 901768-34-1 CAPLUS

CN 3-Pyridinecarboxamide, 5-fluoro-N-[cis-4-[(2-hydroxy-4-methylbenzoyl)amino]cyclohexyl]-2-[(tetrahydro-2H-thiopyran-4-yl)oxy] - (9CI) (CA INDEX NAME)

Relative stereochemistry.



IT 901768-35-2P

RL: PEP (Physical, engineering or chemical process); PRP (Properties); PYP (Physical process); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); PROC (Process); USES (Uses)


(preparation of polymorphic crystalline forms of

cis-5-fluoro-N-[4-(2-hydroxy-4-methylbenzamido)cyclohexyl]-2-(tetrahydrothiopyran-4-yloxy)nicotinamide)

RN 901768-35-2 CAPLUS

CN 3-Pyridinecarboxamide, 5-fluoro-N-[cis-4-[(2-hydroxy-4-methylbenzoyl)amino]cyclohexyl]-2-[(tetrahydro-2H-thiopyran-4-yl)oxy] -, monohydrate (9CI) (CA INDEX NAME)

Relative stereochemistry.

● H<sub>2</sub>O

REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2007 ACS on STN  
 ACCESSION NUMBER: 2005:78237 CAPLUS  
 DOCUMENT NUMBER: 142:176699  
 TITLE: A preparation of (thiopyranyloxy)pyridinecarboxamide derivatives, useful as TNF- $\alpha$  and PDE4 inhibitors  
 INVENTOR(S): Barber, Christopher Gordon; Bunnage, Mark Edward; Harvey, John Wilson; Mathias, John Paul  
 PATENT ASSIGNEE(S): UK  
 SOURCE: U.S. Pat. Appl. Publ., 52 pp.  
 CODEN: USXXCO  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2005020611	A1	20050127	US 2004-896085	20040720
AU 2004259133	A1	20050203	AU 2004-259133	20040713
AU 2004259526	A1	20050203	AU 2004-259526	20040713
CA 2532249	A1	20050203	CA 2004-2532249	20040713
CA 2533624	A1	20050203	CA 2004-2533624	20040713
WO 2005009994	A1	20050203	WO 2004-IB2367	20040713
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
WO 2005009995	A1	20050203	WO 2004-IB2380	20040713
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				

RW:	BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
EP 1651640	A1	20060503	EP 2004-744026	20040713
EP 1651640	B1	20070214		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR				
EP 1651641	A1	20060503	EP 2004-744038	20040713
EP 1651641	B1	20070523		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR				
CN 1829712	A	20060906	CN 2004-80021550	20040713
BR 2004012834	A	20060926	BR 2004-12834	20040713
BR 2004012910	A	20060926	BR 2004-12910	20040713
CN 1860113	A	20061108	CN 2004-80027996	20040713
JP 2006528625	T	20061221	JP 2006-520935	20040713
JP 2006528657	T	20061221	JP 2006-521682	20040713
AT 353893	T	20070315	AT 2004-744026	20040713
AT 362930	T	20070615	AT 2004-744038	20040713
US 2005043326	A1	20050224	US 2004-896068	20040720
NL 1026716	A1	20050126	NL 2004-1026716	20040723
NL 1026716	C2	20051005		
NL 1026717	A1	20050126	NL 2004-1026717	20040723
NL 1026717	C2	20051101		
IN 2006DN00129	A	20070824	IN 2006-DN129	20060109
US 2006178408	A1	20060810	US 2006-564694	20060111
NO 2006000314	A	20060406	NO 2006-314	20060120
MX 2006PA00936	A	20060330	MX 2006-PA936	20060124
MX 2006PA00986	A	20060411	MX 2006-PA986	20060125
NO 2006000963	A	20060227	NO 2006-963	20060227
PRIORITY APPLN. INFO.:			GB 2003-17498	A 20030725
			US 2003-497120P	P 20030822
			WO 2004-IB2367	W 20040713
			WO 2004-IB2380	W 20040713

OTHER SOURCE(S) :

MARPAT 142:176699

GI

\* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT \*

AB The invention relates to a preparation of (thiopyranyloxy)pyridinecarboxamide derivs. of formula I [wherein: R1 is H, halogen, or alkyl; R2 is Ph, Bn, naphthyl, or heteroaryl, etc.; Z is C(O) or SO<sub>2</sub>], useful as TNF- $\alpha$  and PDE4 inhibitors. For instance, (thiopyranyloxy)pyridinecarboxamide derivative II (TNF- $\alpha$  inhibition: IC<sub>50</sub> = 0.7 nM) was prepared via amidation of 4-hydroxy-2-methoxybenzoic acid by amine III•HCl with a yield of 64%.

IT 834868-51-8P 834868-53-0P 834868-55-2P  
 834868-57-4P 834868-59-6P 834868-61-0P  
 834868-62-1P 834868-63-2P 834868-64-3P  
 834868-65-4P 834868-66-5P 834868-67-6P  
 834868-68-7P 834868-70-1P 834868-72-3P  
 834868-73-4P 834868-74-5P 834868-75-6P  
 834868-76-7P 834868-77-8P 834868-78-9P  
 834868-80-3P 834868-83-6P 834868-86-9P  
 834868-89-2P 834868-90-5P 834868-91-6P  
 834868-93-8P 834868-94-9P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES

11/564,694


(Uses)

(preparation of (thiopyranloxy)pyridinecarboxamide derivs. useful as TNF- $\alpha$  and PDE4 inhibitors)

RN 834868-51-8 CAPLUS

CN 3-Pyridinecarboxamide, 5-fluoro-N-[cis-4-[(4-hydroxy-2-methoxybenzoyl)amino]cyclohexyl]-2-[(tetrahydro-2H-thiopyran-4-yl)oxy]-(9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 834868-53-0 CAPLUS

CN 3-Pyridinecarboxamide, 5-fluoro-N-[cis-4-[[[5-(2-methoxyphenyl)-1H-pyrazol-3-yl]carbonyl]amino]cyclohexyl]-2-[(tetrahydro-2H-thiopyran-4-yl)oxy]-(9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 834868-55-2 CAPLUS

CN Imidazo[1,2-a]pyridine-8-carboxamide, N-[cis-4-[[[5-fluoro-2-[(tetrahydro-2H-thiopyran-4-yl)oxy]-3-pyridinyl]carbonyl]amino]cyclohexyl]-7-methoxy-(9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 834868-57-4 CAPLUS

CN 3-Pyridinecarboxamide, 5-fluoro-N-[cis-4-[(2-hydroxyethoxy)benzoyl]amino]cyclohexyl]-2-[(tetrahydro-2H-thiopyran-4-yl)oxy]- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 834868-59-6 CAPLUS

CN 3-Pyridinecarboxamide, 5-fluoro-N-[cis-4-[(2-hydroxyethoxy)-5-methylbenzoyl]amino]cyclohexyl]-2-[(tetrahydro-2H-thiopyran-4-yl)oxy]- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 834868-61-0 CAPLUS

CN 3-Pyridinecarboxamide, N-[cis-4-[(3-chloro-2-(2-hydroxyethoxy)benzoyl)amino]cyclohexyl]-5-fluoro-2-[(tetrahydro-2H-

11/564,694

thiopyran-4-yl)oxy]- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 834868-62-1 CAPLUS

CN 3-Pyridinecarboxamide, N-[cis-4-[[4-chloro-2-(2-hydroxyethoxy)benzoyl]amino]cyclohexyl]-5-fluoro-2-[(tetrahydro-2H-thiopyran-4-yl)oxy]- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 834868-63-2 CAPLUS

CN 3-Pyridinecarboxamide, N-[cis-4-[[5-chloro-2-(2-hydroxyethoxy)benzoyl]amino]cyclohexyl]-5-fluoro-2-[(tetrahydro-2H-thiopyran-4-yl)oxy]- (9CI) (CA INDEX NAME)

Relative stereochemistry.




11/564,694

RN 834868-64-3 CAPLUS

CN 3-Pyridinecarboxamide, 5-fluoro-N-[cis-4-[[2-(2-hydroxyethoxy)-3-methylbenzoyl]amino]cyclohexyl]-2-[(tetrahydro-2H-thiopyran-4-yl)oxy]-(9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 834868-65-4 CAPLUS

CN 3-Pyridinecarboxamide, 5-fluoro-N-[cis-4-[[2-(2-hydroxyethoxy)-4-methylbenzoyl]amino]cyclohexyl]-2-[(tetrahydro-2H-thiopyran-4-yl)oxy]-(9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 834868-66-5 CAPLUS

CN 3-Pyridinecarboxamide, N-[cis-4-[[2-(2-hydroxyethoxy)-5-methylbenzoyl]amino]cyclohexyl]-2-[(tetrahydro-2H-thiopyran-4-yl)oxy]-(9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 834868-67-6 CAPLUS

CN 3-Pyridinecarboxamide, N-[cis-4-[(2-(2-hydroxyethoxy)-4-methylbenzoyl)amino]cyclohexyl]-2-[(tetrahydro-2H-thiopyran-4-yl)oxy]- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 834868-68-7 CAPLUS

CN 3-Pyridinecarboxamide, N-[cis-4-[(2-(2-hydroxyethoxy)benzoyl)amino]cyclohexyl]-5-methyl-2-[(tetrahydro-2H-thiopyran-4-yl)oxy]- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 834868-70-1 CAPLUS

CN 3-Pyridinecarboxamide, 5-fluoro-N-[cis-4-[(2-(3-hydroxypropoxy)benzoyl)amino]cyclohexyl]-2-[(tetrahydro-2H-thiopyran-4-yl)oxy]- (9CI) (CA INDEX NAME)

11/564,694


Relative stereochemistry.



RN 834868-72-3 CAPLUS

CN 3-Pyridinecarboxamide, N-[cis-4-[[5-ethyl-2-(2-hydroxyethoxy)benzoyl]amino]cyclohexyl]-5-fluoro-2-[(tetrahydro-2H-thiopyran-4-yl)oxy]- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 834868-73-4 CAPLUS

CN 3-Pyridinecarboxamide, N-[cis-4-[[4-ethyl-2-(2-hydroxyethoxy)benzoyl]amino]cyclohexyl]-5-fluoro-2-[(tetrahydro-2H-thiopyran-4-yl)oxy]- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 834868-74-5 CAPLUS

CN 3-Pyridinecarboxamide, 5-fluoro-N-[cis-4-[[2-(2-hydroxyethoxy)-4-(1-

11/564,694

[methylethyl]benzoyl]amino]cyclohexyl]-2-[(tetrahydro-2H-thiopyran-4-yl)oxy]- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 834868-75-6 CAPLUS

CN 3-Pyridinecarboxamide, 5-fluoro-N-[cis-4-[[2-(2-hydroxyethoxy)-5-(1-methylethyl)benzoyl]amino]cyclohexyl]-2-[(tetrahydro-2H-thiopyran-4-yl)oxy]- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 834868-76-7 CAPLUS

CN 3-Pyridinecarboxamide, 5-fluoro-N-[cis-4-[[2-(3-hydroxypropoxy)-4-methylbenzoyl]amino]cyclohexyl]-2-[(tetrahydro-2H-thiopyran-4-yl)oxy]- (9CI) (CA INDEX NAME)

Relative stereochemistry.




11/564,694

RN 834868-77-8 CAPLUS

CN 3-Pyridinecarboxamide, 5-fluoro-N-[cis-4-[[5-fluoro-2-(2-hydroxyethoxy)benzoyl]amino]cyclohexyl]-2-[(tetrahydro-2H-thiopyran-4-yl)oxy]- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 834868-78-9 CAPLUS

CN 3-Pyridinecarboxamide, N-[cis-4-[[3,5-dichloro-2-(2-hydroxyethoxy)benzoyl]amino]cyclohexyl]-5-fluoro-2-[(tetrahydro-2H-thiopyran-4-yl)oxy]- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 834868-80-3 CAPLUS

CN 3-Pyridinecarboxamide, N-[cis-4-[(2-ethoxy-4-hydroxybenzoyl)amino]cyclohexyl]-5-fluoro-2-[(tetrahydro-2H-thiopyran-4-yl)oxy]- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 834868-83-6 CAPLUS

CN 3-Pyridinecarboxamide, N-[cis-4-[(2-(cyclopropylmethoxy)-4-hydroxybenzoyl)amino]cyclohexyl]-5-fluoro-2-[(tetrahydro-2H-thiopyran-4-yl)oxy]- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 834868-86-9 CAPLUS

CN 3-Pyridinecarboxamide, N-[cis-4-[(2-(cyclopentyloxy)-4-hydroxybenzoyl)amino]cyclohexyl]-5-fluoro-2-[(tetrahydro-2H-thiopyran-4-yl)oxy]- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 834868-89-2 CAPLUS

CN 3-Pyridinecarboxamide, 5-fluoro-N-[cis-4-[(5-methoxy-2,1,3-benzothiadiazol-4-yl)sulfonyl]amino]cyclohexyl]-2-[(tetrahydro-2H-

11/564,694

thiopyran-4-yl)oxy] - (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 834868-90-5 CAPLUS

CN 3-Pyridinecarboxamide, N-[cis-4-[(5-methoxy-2,1,3-benzothiadiazol-4-yl)sulfonyl]amino]cyclohexyl]-2-[(tetrahydro-2H-thiopyran-4-yl)oxy] - (9CI)  
(CA INDEX NAME)


Relative stereochemistry.



RN 834868-91-6 CAPLUS

CN 3-Pyridinecarboxamide, N-[cis-4-[(2-methoxy-5-methylphenyl)sulfonyl]amino]cyclohexyl]-2-[(tetrahydro-2H-thiopyran-4-yl)oxy] - (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 834868-93-8 CAPLUS

CN 3-Pyridinecarboxamide, 5-fluoro-N-[cis-4-[(7-methoxy-8-

11/564,694

quinolinylsulfonyl]amino)cyclohexyl]-2-[(tetrahydro-2H-thiopyran-4-yl)oxy]- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 834868-94-9 CAPLUS

CN 3-Pyridinecarboxamide, N-[cis-4-[(7-methoxy-8-quinolinyl)sulfonyl]amino)cyclohexyl]-2-[(tetrahydro-2H-thiopyran-4-yl)oxy]- (9CI) (CA INDEX NAME)

Relative stereochemistry.



IT 834868-52-9P 834868-58-5P 834868-60-9P

834868-69-8P 834868-71-2P 834868-81-4P

834868-85-8P 834868-87-0P 834868-88-1P

834868-98-3P 834868-99-4P 834869-00-0P

834869-01-1P 834869-02-2P 834869-03-3P

834869-41-9P 834869-43-1P 834869-44-2P

834869-45-3P


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of (thiopyranyloxy)pyridinecarboxamide derivs. useful as TNF- $\alpha$  and PDE4 inhibitors)

RN 834868-52-9 CAPLUS

CN 3-Pyridinecarboxamide, N-(cis-4-aminocyclohexyl)-5-fluoro-2-[(tetrahydro-2H-thiopyran-4-yl)oxy]-, monohydrochloride (9CI) (CA INDEX NAME)

Relative stereochemistry.




● HCl

RN 834868-58-5 CAPLUS

CN 3-Pyridinecarboxamide, 5-fluoro-N-[cis-4-[(2-[(tetrahydro-2H-pyran-2-yl)oxy]ethoxy]benzoyl]amino]cyclohexyl]-2-[(tetrahydro-2H-thiopyran-4-yl)oxy]- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 834868-60-9 CAPLUS

CN 3-Pyridinecarboxamide, 5-fluoro-N-[cis-4-[(5-methyl-2-[(tetrahydro-2H-pyran-2-yl)oxy]ethoxy]benzoyl]amino]cyclohexyl]-2-[(tetrahydro-2H-thiopyran-4-yl)oxy]- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 834868-69-8 CAPLUS

CN 3-Pyridinecarboxamide, N-(cis-4-aminocyclohexyl)-5-methyl-2-[(tetrahydro-2H-thiopyran-4-yl)oxy]-, monohydrochloride (9CI) (CA INDEX NAME)

Relative stereochemistry.




● HCl

RN 834868-71-2 CAPLUS

CN 3-Pyridinecarboxamide, 5-fluoro-N-[cis-4-[(2-hydroxybenzoyl)amino]cyclohexyl]-2-[(tetrahydro-2H-thiopyran-4-yl)oxy]- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 834868-81-4 CAPLUS

CN 3-Pyridinecarboxamide, N-[cis-4-[(2-ethoxy-4-(phenylmethoxy)benzoyl]amino]cyclohexyl]-5-fluoro-2-[(tetrahydro-2H-thiopyran-4-yl)oxy]- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 834868-85-8 CAPLUS

CN 3-Pyridinecarboxamide, N-[cis-4-[(2-(cyclopropylmethoxy)-4-(phenylmethoxy)benzoyl]amino]cyclohexyl]-5-fluoro-2-[(tetrahydro-2H-thiopyran-4-yl)oxy]- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 834868-87-0 CAPLUS

CN 3-Pyridinecarboxamide, N-[cis-4-[(2-(cyclopentyloxy)-4-(phenylmethoxy)benzoyl]amino]cyclohexyl]-5-fluoro-2-[(tetrahydro-2H-

11/564,694

thiopyran-4-yl)oxy] - (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 834868-88-1 CAPLUS

CN 3-Pyridinecarboxamide, N-(cis-4-aminocyclohexyl)-2-[(tetrahydro-2H-thiopyran-4-yl)oxy]-, monohydrochloride (9CI) (CA INDEX NAME)

Relative stereochemistry.




● HCl

RN 834868-98-3 CAPLUS

CN Carbamic acid, [cis-4-[[[5-fluoro-2-[(tetrahydro-2H-thiopyran-4-yl)oxy]-3-pyridinyl]carbonyl]amino]cyclohexyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Relative stereochemistry.




11/564,694

RN 834868-99-4 CAPLUS

CN Carbamic acid, [cis-4-[[[5-chloro-2-[(tetrahydro-2H-thiopyran-4-yl)oxy]-3-pyridinyl]carbonyl]amino]cyclohexyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 834869-00-0 CAPLUS

CN Carbamic acid, [cis-4-[[[5-methyl-2-[(tetrahydro-2H-thiopyran-4-yl)oxy]-3-pyridinyl]carbonyl]amino]cyclohexyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 834869-01-1 CAPLUS

CN Carbamic acid, [cis-4-[[[2-[(tetrahydro-2H-thiopyran-4-yl)oxy]-3-pyridinyl]carbonyl]amino]cyclohexyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Relative stereochemistry.




11/564,694

RN 834869-02-2 CAPLUS

CN 3-Pyridinecarboxamide, N-(cis-4-aminocyclohexyl)-5-fluoro-2-[(tetrahydro-2H-thiopyran-4-yl)oxy]- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 834869-03-3 CAPLUS

CN 3-Pyridinecarboxamide, N-(cis-4-aminocyclohexyl)-5-chloro-2-[(tetrahydro-2H-thiopyran-4-yl)oxy]-, monohydrochloride (9CI) (CA INDEX NAME)

Relative stereochemistry.




● HCl

RN 834869-41-9 CAPLUS

CN 3-Pyridinecarboxamide, 5-fluoro-N-[cis-4-[[2-(phenylmethoxy)-5-(trifluoromethyl)benzoyl]amino]cyclohexyl]-2-[(tetrahydro-2H-thiopyran-4-yl)oxy]- (9CI) (CA INDEX NAME)

Relative stereochemistry.


11/564,694



RN 834869-43-1 CAPLUS

CN 1H-Indazole-3-carboxamide, N-[cis-4-[[[5-fluoro-2-[(tetrahydro-2H-thiopyran-4-yl)oxy]-3-pyridinyl]carbonyl]amino]cyclohexyl]-1-[2-[(tetrahydro-2H-pyran-2-yl)oxy]ethyl]- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 834869-44-2 CAPLUS

CN 3-Pyridinecarboxamide, 5-fluoro-N-[cis-4-[[[5-methyl-1-[2-[(tetrahydro-2H-pyran-2-yl)oxy]ethyl]-1H-pyrazol-3-yl]carbonyl]amino]cyclohexyl]-2-[(tetrahydro-2H-thiopyran-4-yl)oxy]- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 834869-45-3 CAPLUS

CN 3-Pyridinecarboxamide, 5-fluoro-N- [cis-4- [[4-(phenylmethoxy)benzoyl]amino]cyclohexyl]-2- [(tetrahydro-2H-thiopyran-4-yl)oxy]- (9CI) (CA INDEX NAME)

Relative stereochemistry.



=>